半夏泻心汤联合西医三联抗Hp疗法治疗慢性萎缩性胃炎的临床效果
|
摘要
目的分析半夏泻心汤联合西医三联抗幽门螺杆菌(Hp)疗法治疗萎缩性胃炎的临床效果。方法选取我院2016年12月至2018年12月收治的100例慢性萎缩性胃炎患者,按非随机非劣效性将其分为对照组和观察组,各50例。对照组采用西医三联抗Hp疗法,观察组采用西医三联抗Hp疗法联合半夏泻心汤。对比两组的治疗效果。结果观察组Hp根除率为96.00%,高于对照组的70.00%(P<0.05)。治疗后,两组的中医症候评分显著降低,且观察组明显低于对照组,差异有统计学意义(P<0.05)。观察组患者胃痛、恶心呕吐、嗳气反酸及纳差消失时间均短于对照组,差异有统计学意义(P<0.05)。观察组的治疗总有效率为94.00%,高于对照组的66.00%(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗后,两组患者的血清G-17水平均降低,且观察组低于对照组(P<0.05)。结论半夏泻心汤联合西医三联抗Hp疗法治疗慢性萎缩性胃炎的效果显著,可改善患者的临床症状,提高Hp根除率,安全性高,值得临床推广应用。
Objective To analyze the clinical effect of Banxia Xiexin decoction combined with western medicine triple anti-Helicobacter pylori(Hp) therapy on chronic atrophic gastritis. Methods One hundred patients with chronic atrophic gastritis admitted in our hospital from December 2016 to December 2018 were selected and divided into control group and observation group according to the non-random and non-inferior efficacy, with 50 cases in each group. The control group was treated with western medicine triple anti-Hp therapy, while the observation group was treated with western medicine triple anti-Hp therapy combined with Banxia Xiexin decoction. The therapeutic effects were compared between the two groups. Results The eradication rate of Hp in the observation group was 96.00%, which was higher than 70.00%in the control group(P<0.05). After treatment, the scores of TCM symptoms in the two groups significantly reduced, and that of the observation group was significantly lower than the control group(P <0.05). The disappearance time of stomachache, nausea and vomiting, acid regurgitation and anorexia in the observation group were shorter than those in the control group, and the differences were statistically significant(P <0.05). The total effective rate of treatment in the observation group was 94.00%, which was higher than 66.00% in the control group(P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). After treatment, the serum G-17 level in both groups decreased, and that of the observation group was lower than the control group(P<0.05). Conclusion Banxia Xiexin decoction combined with western medicine triple anti-Hp therapy is effective in treating chronic atrophic gastritis, which can improve the clinical symptoms of patients and the eradication rate of Hp. It is safe and worthy of clinical application.
Objective To analyze the clinical effect of Banxia Xiexin decoction combined with western medicine triple anti-Helicobacter pylori(Hp) therapy on chronic atrophic gastritis. Methods One hundred patients with chronic atrophic gastritis admitted in our hospital from December 2016 to December 2018 were selected and divided into control group and observation group according to the non-random and non-inferior efficacy, with 50 cases in each group. The control group was treated with western medicine triple anti-Hp therapy, while the observation group was treated with western medicine triple anti-Hp therapy combined with Banxia Xiexin decoction. The therapeutic effects were compared between the two groups. Results The eradication rate of Hp in the observation group was 96.00%, which was higher than 70.00%in the control group(P<0.05). After treatment, the scores of TCM symptoms in the two groups significantly reduced, and that of the observation group was significantly lower than the control group(P <0.05). The disappearance time of stomachache, nausea and vomiting, acid regurgitation and anorexia in the observation group were shorter than those in the control group, and the differences were statistically significant(P <0.05). The total effective rate of treatment in the observation group was 94.00%, which was higher than 66.00% in the control group(P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). After treatment, the serum G-17 level in both groups decreased, and that of the observation group was lower than the control group(P<0.05). Conclusion Banxia Xiexin decoction combined with western medicine triple anti-Hp therapy is effective in treating chronic atrophic gastritis, which can improve the clinical symptoms of patients and the eradication rate of Hp. It is safe and worthy of clinical application.
引文
[1]刘京运,金世禄.慢性萎缩性胃炎患病率与年龄的关系及发病的影响因素[J].川北医学院学报,2017,32(1):152-154.
[2]张峰,王卫国,谢燕,等.慢性萎缩性胃炎胃镜与病理诊断的符合率及与Hp感染的相关性分析[J].临床和实验医学杂志,2016,15(23):2325-2327.
[3]黄雅慧,郭菊清,刘越洋,等.慢性萎缩性胃炎胃黏膜癌前病变病理变化与中医证型及Hp的相关性研究[J].中华中医药学刊,2014,32(6):1381-1383.
[4]张声生,唐旭东,黄穗平,等.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064.
[5]房静远,刘文忠,李兆申,等.中国慢性胃炎共识意见(2012年,上海)[J].中国医学前沿杂志:电子版,2013,5(7):44-55.
[6] TONG Y,WU Y,SONG Z,et al.The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China:a diagnostic clinical research[J].BMC Gastroenterol,2017,17(1):88.
[7]宗湘裕,王万卷,刘宝珍,等.慢性萎缩性胃炎中医证型与幽门螺杆菌感染、病理分级的相关性研究[J].现代中西医结合杂志,2015,24(4):370-372.
[8]方小鹤,赵平,王江滨.血清胃泌素17在慢性萎缩性胃炎患者中的表达水平及意义[J].中国老年学杂志,2015,35(5):1290-1291.
[9]尹利顺,孙蓉.吴茱萸挥发油化学成分与药理毒理研究进展[J].中国药物警戒,2016,13(3):162-164.
[10]刘永红,郭建宏,刘文婷,等.药用植物半夏生物碱类成分研究进展[J].西北农林科技大学学报:自然科学版,2015,43(9):171-177.
[11]马善美,郑卫,张筠,等.半夏泻心汤结合三联抗Hp方案治疗胃癌前病变患者临床疗效及对预后的影响[J].临床合理用药杂志,2017,10(32):6-8.
[2]张峰,王卫国,谢燕,等.慢性萎缩性胃炎胃镜与病理诊断的符合率及与Hp感染的相关性分析[J].临床和实验医学杂志,2016,15(23):2325-2327.
[3]黄雅慧,郭菊清,刘越洋,等.慢性萎缩性胃炎胃黏膜癌前病变病理变化与中医证型及Hp的相关性研究[J].中华中医药学刊,2014,32(6):1381-1383.
[4]张声生,唐旭东,黄穗平,等.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(7):3060-3064.
[5]房静远,刘文忠,李兆申,等.中国慢性胃炎共识意见(2012年,上海)[J].中国医学前沿杂志:电子版,2013,5(7):44-55.
[6] TONG Y,WU Y,SONG Z,et al.The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China:a diagnostic clinical research[J].BMC Gastroenterol,2017,17(1):88.
[7]宗湘裕,王万卷,刘宝珍,等.慢性萎缩性胃炎中医证型与幽门螺杆菌感染、病理分级的相关性研究[J].现代中西医结合杂志,2015,24(4):370-372.
[8]方小鹤,赵平,王江滨.血清胃泌素17在慢性萎缩性胃炎患者中的表达水平及意义[J].中国老年学杂志,2015,35(5):1290-1291.
[9]尹利顺,孙蓉.吴茱萸挥发油化学成分与药理毒理研究进展[J].中国药物警戒,2016,13(3):162-164.
[10]刘永红,郭建宏,刘文婷,等.药用植物半夏生物碱类成分研究进展[J].西北农林科技大学学报:自然科学版,2015,43(9):171-177.
[11]马善美,郑卫,张筠,等.半夏泻心汤结合三联抗Hp方案治疗胃癌前病变患者临床疗效及对预后的影响[J].临床合理用药杂志,2017,10(32):6-8.